LAWRENCE FONG

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Fluorine F 18 Ara-G
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-01-02

Last Posted Date: 2020-01-21

Lead Sponsor: Lawrence Fong

Target Recruit Count: 4

Registration Number: NCT03007719

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms

Interventions: Biological: PROSTVAC V/F
Drug: Ipilimumab

First Posted Date: 2015-07-22

Last Posted Date: 2021-11-24

Lead Sponsor: Lawrence Fong

Target Recruit Count: 15

Registration Number: NCT02506114

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Neoadjuvant Atezolizumab in Localized Bladder Cancer

Phase 2

Completed

Conditions: Carcinoma, Transitional Cell

Interventions: Drug: Atezolizumab

First Posted Date: 2015-05-22

Last Posted Date: 2024-05-31

Lead Sponsor: Lawrence Fong

Target Recruit Count: 23

Registration Number: NCT02451423

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab
Drug: GM-CSF

First Posted Date: 2012-02-10

Last Posted Date: 2015-10-05

Lead Sponsor: Lawrence Fong

Registration Number: NCT01530984

Locations: 🇺🇸
University of California, San Francisco, California, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy